IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome
The Journal of Immunology · 01.06.2023 · 210 (11) · 1790-1803
DOI: 10.4049/jimmunol.2300065 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 19.04.2023. Verfasst von Mathilde Harel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Anemia, Macrophage Activation Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fondation Rheumasearch.
Abstract (Originalsprache)
IL-18 is a pleiotropic immunoregulatory cytokine of the IL-1 family. IL-18 has been identified as a potent IFN-γ inducer in synergy with IL-12 and IL-15 and thus as a powerful Th1 cell–polarizing cytokine. IL-18 activity is regulated by its naturally occurring soluble inhibitor IL-18 binding protein (IL-18BP), the production of which is stimulated by IFN-γ in a negative feedback loop. Circulating levels of IL-18BP are elevated, and unbound bioactive free IL-18 is thus not detectable in the circulation in physiologic conditions. However, emerging evidence indicates that the IL-18/IL-18BP balance could be dysregulated in macrophage activation syndrome (MAS), as mirrored by the presence of free IL-18 in the circulation of patients with MAS. Herein, we sought to identify IL-18BP-producing cells in a murine CpG-induced MAS model using IL-18BP knock-in tdTomato reporter mice. Endothelial cells, tissue-resident macrophages, and neutrophils appeared as major cellular sources of IL-18BP. We also identified extramedullary and medullary early erythroid progenitors as IL-18BP-producing cells in an IFN-γ-dependent manner. This finding suggests a novel regulation of IL-18 activity by erythroid precursors, which are likely involved in the prevention of the negative effects of IL-18 on erythropoiesis. Indeed, coherent in vivo and in vitro results indicate that IL-18 indirectly impairs erythropoiesis while favoring myelopoiesis and thus contributes to anemia associated with MAS and potentially with other IL-18-driven inflammatory diseases. In conclusion, IL-18BP production by endothelial cells, neutrophils, macrophages, and erythroid precursors attenuates the anemia associated with murine CpG-induced MAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, University Hospitals, Geneva, Switzerland.
- Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
ORCID-Profile: Gaby Palmer, Cem Gabay
Förderung
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Fondation Rheumasearch
- EC | HORIZON EUROPE Framework Programme
Zitieren
APA
Harel, M., Fauteux-Daniel, S., Rodriguez, E., Palmer, G., & Gabay, C. (2023). IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome. The Journal of Immunology, 210(11), 1790-1803. https://doi.org/10.4049/jimmunol.2300065
Vancouver
Harel M, Fauteux-Daniel S, Rodriguez E, Palmer G, Gabay C. IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome. The Journal of Immunology. 2023;210(11):1790-1803. doi:10.4049/jimmunol.2300065
BibTeX
@article{Harel2023,
author = {Harel, Mathilde and Fauteux-Daniel, Sébastien and Rodriguez, Emiliana and Palmer, Gaby and Gabay, Cem},
title = {IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome},
journal = {The Journal of Immunology},
year = {2023},
volume = {210},
number = {11},
pages = {1790--1803},
doi = {10.4049/jimmunol.2300065}
}
EUVIMED